Rocket Lab (NASDAQ: RKLB) trades at $63.92, a level that sits well below its 52-week high of $151, representing a peak-to-current drawdown exceeding 57%.
Despite the steep decline, Wall Street analysts have not retreated, with consensus price targets implying roughly 77% upside from current trading levels.
KeyBanc carries the Street-high target at $135.00, implying approximately 111% upside, after analyst Michael Leshock upgraded the stock to Overweight.
Leshock cited Rocket Lab as the clear number two challenger to SpaceX in commercial launch, pointing to high conviction in the Neutron medium-lift vehicle and structural undersupply of global launch capacity as key reasons for his bullish stance.
A $397 million Flatellite award for the U.S. Space Force SB-AMTI program anchors a growing defense book that adds further weight to the analyst’s thesis.
Q2 revenue of $234.07 million beat the consensus estimate of $230.94 million, growing 62.0% year over year, though GAAP EPS of -$0.08 narrowly missed expectations due to $8.576 million in acquisition costs.
Backlog jumped 137% year over year to $2.36 billion, with management booking more than $1 billion in new contracts during Q3, underscoring the disconnect between operational momentum and share price performance.
Across 18 analysts tracked, the ratings breakdown stands at 3 Strong Buy, 11 Buy, 4 Hold, and 0 Sell or Strong Sell ratings, a distribution that reflects unusually firm conviction for a stock under this much pressure.
The key uncertainty remains the Neutron rocket, with CEO Peter Beck warning that “the window for an end-of-year launch is narrowing,” casting doubt on a Q4 2026 pad delivery target.
CFO Adam Spice added that meaningful cash-flow improvement likely follows Neutron’s test flight by 18 to 24 months, framing the real financial payoff as a 2027 story at the earliest.
Alongside Neutron timing risk, a $1.53 billion ATM equity raise in the first half and integration complexity from the Mynaric, Motiv, and Iridium acquisitions are feeding investor caution in the near term.
The stock carries a beta of 2.629 and trades at 53x trailing sales, meaning the math behind any price target assumes the growth curve compounds without a major operational stumble.
RKLB is down 8.37% year to date while the S&P 500 has climbed 12.48%, a roughly 21-point relative performance gap that has widened frustration among shareholders who bought into the growth narrative earlier.
Peers including AST SpaceMobile (NASDAQ: ASTS), Planet Labs (NYSE: PL), and Intuitive Machines (NASDAQ: LUNR) are all trading well below analyst consensus targets, suggesting sector-wide skepticism rather than company-specific failure alone.
Planet Labs shows the largest implied upside among peers at roughly 102%, but RKLB holds the cleanest ratings distribution in the group, giving KeyBanc’s $135 target added relevance within a broadly discounted sector.
The bull case hinges on Neutron reaching the pad in Q4 2026, a successful early 2027 test flight, and the Iridium deal closing on schedule to layer recurring communications revenue onto an already expanding backlog.
The bear case builds quickly if Neutron slips further, the ATM equity program continues diluting shareholders, and simultaneous integrations turn 2027 into damage control rather than the scaling story analysts are pricing in.
At current levels, RKLB represents a high-risk, high-conviction setup where the first Neutron launch remains the single most important catalyst for closing the gap between share price and analyst targets.
